Leukemia
This journal publishes high quality, peer reviewed research that covers all aspects of the research and treatment of leukemia and allied diseases. Topics of interest include oncogenes, growth factors, stem cells, leukemia genomics, cell cycle, signal transduction and molecular targets for therapy.
Emerging maturation stage-associated markers predict AML subtype vulnerability to cardiac glycosides: a step towards their repurposing?
A new marker associated with AML maturation predicts the AML blast response to cardiac glycosides, a class of agents used for treating arrhythmia but still waiting for a repurposing opportunity in cancer, and identifies approved regimens that would benefit from the addition of these drugs.
Secondary versus de novo ontogeny for AML in the era of molecular genetics
AML has long been classified and prognosticated based on ontogeny, that is, whether it is de novo or secondary. But several reports have suggested that disease genetics drive these outcomes as opposed to ontogeny. Here, we examine this relationship in greater detail.
Identification of leukemia-initiating cells by transcriptome profiling in a mouse model
Transcriptome profiling and identification of leukemia-initiating cells in a mouse model expressing the fusion gene CBFB-MYH11, which results from chromosome 16 inversion, a common chromosome abnormality in human acute myeloid leukemia.
Culture-associated DNA hypermethylation of CAR T cells negatively affects therapeutic outcome
Analyzing effects of vitro expansion on the methylome of chimeric antigen receptor (CAR) T cells revealed loci with increased methylation that were also associated with reduced long-term survival in patients. These findings suggest that reduced cultivation periods may benefit clinical outcome.
Unusual PDGFRB fusion reveals novel mechanism of kinase activation in Ph-like B-ALL
The detailed functional study of rare and unusual genomic events in patient cancer samples can provide some unique and important biological insights. We have uncovered a novel mechanism of tyrosine kinase activation in a form of leukaemia in which tyrosine kinase activation is the hallmark.